Led the US payer evidence team, providing oversight across the entire respiratory and immunology (R&I) and vaccines and immunotherapies (V&I) franchises; managed medical evidence budgets for multiple brands and supported project governance and contracting processes. Hired and on-boarded new permanent and contracting staff. Responsible for day to day evidence planning and execution of studies for AIRSUPRA, BREZTRI and EVUSHELD/AZD5156; developed pre-launch evidence plans with market access lead for SAPHNELO. Collaborated cross-functionally with global payer, US market access and global medical evidence teams to develop strategic brand priorities. Worked with brand Core Value Teams, Core Medical Teams, Clinical Value & Outcomes (Payer Medical) and Value Strategy and Evidence to provide both clinical and real-world evidence insights for the development of innovative value strategies, contracting/pricing projects and payer value proposition for all brands.

While concurrently leading the US payer evidence team, led the global COPD medical evidence team in an interim fashion while the permanent lead supported the development of emerging V&I/COVID evidence programs. Oversaw the operation of the Evidence Review Team governance process and coordinated with global MARC R&I medial lead. Provided strategic guidance to local markets (e.g., EU/CAN, China) regarding COPD burden of illness studies and TRIXEO/BREZTRI effectiveness programs, represented evidence activities in both global product and medical team meetings (GPT/GMT) and served in an approval capacity for evidence publications.

Managed several real-world evidence studies for biopharmaceutical industry clients utilizing secondary data sources. Participated in business development activities, developed proposals, study protocols and project reports. Led evidence planning workshop for industry clients.

Led a cross functional team of strategy and IT professionals in the development of data strategy and roadmap; participated in the development of a centralized market intelligence function and collaborated with peers on processes to capture and analyze client/enrollee satisfaction and Net Promoter Score information. Contributed to the development of business strategy material and presentations for recently formed Carelon CEO and Anthem/Elevance senior leadership.

Reported to President and Founder of HealthCore. Oversaw and managed investment funding to support four key business growth initiatives focused on the expansion of site-based real-world evidence research services ($30 million over 3 years) and represented HealthCore in Anthem Transformation Office (TO) meetings with C-suite executives. Participated in the evaluation, acquisition and integration of New England Research Institute (NERI). Collaborated with Anthem Health Care Analytics (HCA) leadership to obtain funding for clinical data acquisition team, established overall strategic business priorities for team, represented HealthCore in steering committee meetings and outreach efforts to local/state health information exchanges and oversaw activities related to on-boarding of the clinical data. Led the development of a research and data alliance between Anthem, HealthCore and a large technology/data company focused on site-based research services and participated in the evaluation of several business acquisition targets and partnership opportunities. Represented HealthCore’s business needs during the development of the Diversified Business Group (now Carelon) with executive leadership including Anthem Chief Clinical Officer and CEO of Diversified Business Group; collaborated with external strategy consultants (McKinsey, Accenture) to provide strategic direction for creation of new business unit. Conducted an evaluation of pharmacogenomic (PGx) testing and its role within Anthem’s emerging PBM strategy for Anthem Corporate Development/IngenioRx, including strategic evaluation of two dozen potential PGx laboratory partners; aligning strategy with AIM Specialty Health and Ingenio Rx leadership.

Individual contributor role reporting to HealthCore President and Staff Vice President for Strategic Initiatives and Chief of Staff responsible for generating cross-functional collaboration within company on special business initiatives. Led several projects with Anthem and external stakeholders evaluating health management programs to help inform medical decision making. Oversaw internal business operations strategies related to data acquisition, statistical program training and the development of corporate objectives. Conducted research for Anthem on coronary artery disease and treatment guidelines, identified over $100M in cost of care opportunities for health plan, presented findings to Anthem clinical leadership to inform new practice guidelines. Managed team with Anthem senior medical leadership and Memorial Sloan Kettering researchers to examine breast cancer treatment complications, resulting in a publication in the Journal of Oncology Practice. Oversaw the development of a research methods project related to defining health outcomes of interest with senior scientific staff from the Reagan-Udall Foundation and Harvard Pilgrim Health Care Institute with publication in the Journal of Pharmacoepidemiology and Drug Safety. Managed a portfolio of projects for the State of Delaware Medicaid and Delaware Division of Substance Abuse and Mental Health focused on the evaluation of substance abuse dependent treatment programs and related quality of care measures. Championed and oversaw the creation of a process for HealthCore researchers to gain greater access to over 20 million Medicaid administrative claims data lives and worked with Anthem legal and IT leadership to acquire access and secure HealthCore research use rights to third-party carve-out prescription data (10+ million lives).

Individual contributor role providing scientific and research oversight on a portfolio of projects for internal Anthem stakeholders and external life-sciences and payer clients. Mentored new research staff and managed team of data programmers and research analysts on three-year analysis of Empire BCBS (NY) patient-centered medical home (PCMH) initiative, presented results to health plan executives. Served as business lead for HealthCore’s research relationship with the State of Delaware’s Medicaid program, oversaw the acquisition and quality assessment of State of Delaware Medicaid administrative claims data (>250,000 annual members) and led numerous health economic and health policy evaluations using Medicaid data. Worked closely with Secretary of Health and Social Services Dr. Rita Landgraf, Delaware Director of Public Health Dr. Karyl Rattay, and Medical Director for the Delaware Division of Medicaid and Medical Assistance Stephen Groff. Presented results of research activities to Delaware Governor Jack Markell. Lead a four-way research collaboration with HealthCore, the State of Delaware, Christiana Care Health System and AstraZeneca; coordinated the integration of clinical and claims data, obtained IRB approval and aligned research interests across business executives from each organization to examine risk factors and costs associated with maternal and infant health; results published in Journal of Women’s Health and Hospital Pediatrics. Collaborated with Anthem’s episode bundled payment (EBP) team to develop internal EBP evaluation processes; authored analysis plan procedures for EBP team, authored internal methodology papers related to shared savings methodologies and provider-patient attribution approaches.

Responsible for leading monthly updates of US diabetes forecast models; communicated forecast trends to commercial brand lead, brand insight director and finance director. Collaborated with global colleagues and alliance partners (BMS) on long-term forecast models for the diabetes franchise (ONGLYZA, KOMBIGLYZE, FARXIGA). Designed primary research techniques to understand drivers of diabetes care and integrated results to improve performance of diabetes models. Supported pre-launch strategy planning for FARXIGA by developing an Excel-based trialist and repeat prescribing model to simulate cross segment forecast volume and by providing research expertise to Insights and Analytics team activities.

Developed strategic HEOR research plans with business partners (Bristol Myers Squibb) to support clinical development and market launch of an emerging diabetes portfolio including DPP-IV and combination products (ONGLYZA and, KOMBIGLYZE) and a the emerging SGLT-2 class of products (FARXIGA). Provided research and payer insights for Phase III clinical trial end-points. Managed research budget of approximately $3 million annually; oversaw requests for proposals (RFP) and facilitated contracting process on multiple database, modeling and observational studies. Liaised with US and global clinical and commercial stakeholders to ensure HEOR studies strongly supported overall US and global brand strategy; provided guidance on global clinical study program. Collaborated in development of two interactive cost-effectiveness models to support CRESTOR global brand. Managed internal AstraZeneca programming resources for epidemiology studies of CRESTOR patients. Served as advisory board member of The Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) patient survey; directly contributed to the development of PRO and QOL instruments.

Conducted general health economic and outcomes research activities and projects utilizing both primary and secondary data sources; providing statistical programming and medical writing support. Developed several budget impact models for biopharmaceutical clients. Developed qualitative interview survey instruments, conducted interviews with health care providers. Managed over nine health outcomes projects involving retrospective claims data and qualitative interviews for a wide range of therapeutic areas including: depression, cardiovascular disease, gout, insomnia, diabetes, and chronic illnesses.Created program for Anthem’s Workers Compensation (WC) team to profile providers and rank quality of care based upon WC and other data sources.Mentored and trained new research staff in research and business processes.

Served as research consultant to several biopharmaceutical clients, responsible for economic and clinical literature reviews for outcomes projects. Lead analyst/manager for 5 qualitative projects assessing health plan coverage and pricing policies for several novel pharmaceutical treatments for the treatment of depression, severe eye conditions (trauma, bacterial keratitis), combination therapies, asthma, and Crohn’s disease. Conducted studies on therapy patterns for patients with dyslipidemia and hypertension using retrospective claims data and EMRServed as policy analyst and writer on project examining the implications of restrictive Medicare prescription drug formularies on medication choices of the elderly, and evaluation of the Montreal Protocol for Asthma.